TÜBINGEN, Germany / BOSTON, USA – August 15, 2025 – CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA ...

When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...

TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. Pfizer and ...

The merger process reached its formal conclusion on January 6, 2026, with Mainz-based BioNTech SE becoming the sole owner. The operational entity, CureVac Merger B.V., has replaced the original ...

(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Friday that it will receive an upfront settlement of $370 million from CureVac N.V. following the mRNA patent settlement reached between ...

MAINZ, Germany, December 3, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”), representing approximately 81.74% of ...

Curevac N.V. ( (CVAC)) has released its Q3 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. Claim 60% off TipRanks Premium for the data-backed insights and ...

German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer ...

The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the ...